The Rate of Infusion Represents an Important Aspect of Administering Anticancer Agents

References

• Joint Commission International, Joint Commission on Accreditation of Healthcare Organizations. Joint Commission International Accreditation Standards for Hospitals. 7th ed. Oak Brook, IL: Joint Commission Resources; 2020.
   Google Scholar
• Goldspiel B, Hoffman JM, Griffith NL, et al. ASHP guidelines on preventing medication errors with chemotherapy and biotherapy. Am J Health Syst Pharm. 2015;72(8):e6–e35. doi:10.2146/sp150001
   PubMed Web of Science ®Google Scholar
• Dhamija M, Kapoor G, Juneja A. Infusional chemotherapy and medication errors in a tertiary care pediatric cancer unit in a resource-limited setting. J Pediatr Hematol Oncol. 2014;36(7):e412–e415. doi:10.1097/MPH.0000000000000044
   PubMed Web of Science ®Google Scholar
• Zhu LL, Li W, Song P, Zhou Q. Injection device-related risk management toward safe administration of medications: experience in a university teaching hospital in The People’s Republic of China. Ther Clin Risk Manag. 2014;10:165–172. doi:10.2147/TCRM.S59199
   PubMed Web of Science ®Google Scholar
• Park J, You SB, Kim H, et al. Experience of nurses with intravenous fluid monitoring for patient safety: a qualitative descriptive study. Risk Manag Healthc Policy. 2022;15:1783–1793. doi:10.2147/RMHP.S374563
   PubMed Web of Science ®Google Scholar
• Garcia-Alonso A. Improving the chemotherapy process and service to cancer patients. Risk Manag Healthc Policy. 2011;4:41–45. doi:10.2147/RMHP.S16059
   PubMedGoogle Scholar
• Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg. 1999;91(2):221–230. doi:10.3171/jns.1999.91.2.0221
   PubMed Web of Science ®Google Scholar
• Piedbois P, Rougier P; Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301–308. doi:10.1200/JCO.1998.16.1.301
   PubMed Web of Science ®Google Scholar
• Hoshino S, Yamashita Y, Maekawa T, Shirakusa T. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients. Cancer Chemother Pharmacol. 2005;56(6):648–652. doi:10.1007/s00280-004-0985-9
   PubMed Web of Science ®Google Scholar
• Zhou J, Meng R, Sui XH, Meng L, Yang BF. Effects of arsenic trioxide administration styles on leukocytosis. Chin Med Sci J. 2006;21:111–114.
   PubMedGoogle Scholar
• Pasternak AL, Link NA, Richardson CM, Rose PG. Effect of prophylactic extended-infusion carboplatin on incidence of hypersensitivity reactions in patients with ovarian, fallopian tube, or peritoneal carcinomas. Pharmacotherapy. 2016;36:723–730. doi:10.1002/phar.1769
   PubMed Web of Science ®Google Scholar
• O’Cearbhaill R, Zhou Q, Iasonos A, et al. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol. 2010;116:326–331. doi:10.1016/j.ygyno.2009.10.070
   PubMed Web of Science ®Google Scholar
• LaVigne K, Hyman DM, Zhou QC, et al. A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer. Int J Gynecol Cancer. 2018;28(6):1176–1182. doi:10.1097/IGC.0000000000001280
   PubMed Web of Science ®Google Scholar
• Petrioli R, Pascucci A, Francini E, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008;61:105–111. doi:10.1007/s00280-007-0454-3.
   PubMed Web of Science ®Google Scholar
• Huynh T, Crozier N, Anselmo L. Safety outcomes of rapid- versus standard-infusion rate oxaliplatin. J Oncol Pharm Pract. 2023;1:10781552231192007. doi:10.1177/10781552231192007.
   Google Scholar
• Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1989;32(2):198–202. doi:10.1016/s0090-8258(89)80033-2
   PubMed Web of Science ®Google Scholar
• Mense ES, Smit AAJ, Crul M, Franssen EJF. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma. J Clin Pharm Ther. 2019;44:249–257. doi:10.1111/jcpt.12781
   PubMed Web of Science ®Google Scholar
• Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer. 1990;65(4):870–873. doi:10.1002/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D
   PubMed Web of Science ®Google Scholar
• Cranmer LD, Hess LM, Sugihara T, Muntz HG. Cardiac events among patients with sarcoma treated with doxorubicin by method of infusion: a real-world database study. Cancer Rep. 2023;6:e1681. doi:10.1002/cnr2.1681
   Google Scholar
• Cranmer LD, Lu Y, Heise RS, et al. Bolus versus continuous intravenous delivery of doxorubicin in soft-tissue sarcomas: post hoc analysis of a prospective randomized trial (SARC021/TH CR-406). Clin Cancer Res. 2023;29(6):1068–1076. doi:10.1158/1078-0432.CCR-22-1564
   PubMed Web of Science ®Google Scholar
• Perreault S, Baker J, Medoff E, et al. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Support Care Cancer. 2017;25(1):205–208. doi:10.1007/s00520-016-3399-4
   PubMed Web of Science ®Google Scholar
• RxList [homepage on the Internet]. BICNU; 2021. Available from: https://www.rxlist.com/bicnu-drug.htm#indications. Accessed September 24, 2023.
   Google Scholar
• RxList [homepage on the Internet]. Gemzar; 2018. Available from: https://www.rxlist.com/gemzar-drug.htm#dosage. Accessed September 23, 2023.
   Google Scholar
• Khatri A, Williams BW, Fisher J. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours. Br J Cancer. 2014;110(2):304–312. doi:10.1038/bjc.2013.738
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Novello S, De Marinis F, et al. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer. 2006;52:319–325. doi:10.1016/j.lungcan.2006.03.004
   PubMed Web of Science ®Google Scholar
• Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75–82. doi:10.1007/s00432-007-0250-9
   PubMed Web of Science ®Google Scholar
• Lévy E, Piedbois P; Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16:3537–3541. doi:10.1200/JCO.1998.16.11.3537
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Gianni L, Verweij J, et al. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. Anticancer Drugs. 2000;11(5):331–337. doi:10.1097/00001813-200006000-00003
   PubMed Web of Science ®Google Scholar
• Jennens R, Rischin D, Yuen K, Toner G, Millward M. Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel. Gynecol Oncol. 2003;91(1):190–193. doi:10.1016/s0090-8258(03)00459-1
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Mross K, ten Tije AJ, et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol. 2002;20(2):574–581. doi:10.1200/JCO.2002.20.2.574
   PubMed Web of Science ®Google Scholar
• Taira K, Okazaki S, Akiyoshi K, et al. Short bevacizumab infusion as an effective and safe treatment for colorectal cancer. Mol Clin Oncol. 2022;17(3):139. doi:10.3892/mco.2022.2572
   PubMed Web of Science ®Google Scholar
• Yanmaz MT, Guner SI, Satılmıs B, Akyol H, Aydın MA. Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion. Med Oncol. 2014;31(11):276. doi:10.1007/s12032-014-0276-1
   PubMed Web of Science ®Google Scholar
• Makris G, Kantzioura A, Beredima M, Karampola M, Emmanouilides C. Feasibility of rapid infusion of the initial dose of bevacizumab in patients with cancer. J BUON. 2015;20(3):923–927.
   PubMed Web of Science ®Google Scholar
• RxList [homepage on the Internet]. Rituxan; 2021. Available from: http://www.rxlist.com/rituxan-drug/indications-dosage.htm. Accessed September 23, 2023.
   Google Scholar
• Swan JT, Zaghloul HA, Cox JE, Murillo JR Jr. Use of a pharmacy protocol to convert standard rituximab infusions to rapid infusion shortens outpatient infusion clinic visits. Pharmacotherapy. 2014;34(7):686–694. doi:10.1002/phar.1420
   PubMed Web of Science ®Google Scholar
• Moore DC, Gebru T, Plesca D. Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center. J Oncol Pharm Pract. 2021;27(8):1914–1918. doi:10.1177/1078155220977898
   PubMed Web of Science ®Google Scholar
• Stakiw J, Kodad S, LeBlanc R, et al. A Phase II, Open-label study of an accelerated infusion rate of daratumumab in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(7):484–490. doi:10.1016/j.clml.2023.03.006
   PubMed Web of Science ®Google Scholar
• Hamadeh IS, Reese ES, Arnall JR, et al. Safety and cost benefits of the rapid daratumumab infusion protocol. Clin Lymphoma Myeloma Leuk. 2020;20(8):526–532.e1. doi:10.1016/j.clml.2020.02.014
   PubMed Web of Science ®Google Scholar
• Gao L, Lau YK, Wei R, et al. Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach. Cancer Chemother Pharmacol. 2021;87(5):635–645. doi:10.1007/s00280-020-04223-9
   PubMed Web of Science ®Google Scholar
• RxList [homepage on the Internet]. Cyramza; 2022. Available from: https://www.rxlist.com/cyramza-drug.htm#dosage. Accessed September 24, 2023.
   Google Scholar
• Yao D, Shen H, Huang J, Yuan Y, Dai H. Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: a retrospective observational study. Medicine. 2018;97(32):e11822. doi:10.1097/MD.0000000000011822
   PubMed Web of Science ®Google Scholar
• RxList [homepage on the Internet]. Paclitaxel; 2022. Available from: https://www.rxlist.com/paclitaxel/generic-drug.htm. Accessed September 24, 2023.
   Google Scholar
• RxList [homepage on the Internet]. Rituxan; 2021. Available from: https://www.rxlist.com/rituxan-drug.htm#dosage. Accessed September 24, 2023.
   Google Scholar
• Mikkelsen TS, Sparreboom A, Cheng C, et al. Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol. 2011;29(13):1771–1778. doi:10.1200/JCO.2010.32.5340
   PubMed Web of Science ®Google Scholar
• Sao LR, Young FD, Otani IM, Castells MC. Hypersensitivity reactions to platinum agents and taxanes. Clin Rev Allergy Immunol. 2022;62:432–448. doi:10.1007/s12016-021-08877-y
   PubMed Web of Science ®Google Scholar
• O’Malley DM, Vetter MH, Cohn DE, Khan A, Hays JL. Outpatient desensitization in selected patients with platinum hypersensitivity reactions. Gynecol Oncol. 2017;145(3):603–610. doi:10.1016/j.ygyno.2017.03.015
   PubMed Web of Science ®Google Scholar
• RxList [homepage on the Internet]. Abraxane; 2021. Available from: https://www.rxlist.com/abraxane-drug.htm. Accessed September 24, 2023.
   Google Scholar
• Dranitsaris G, Yu B, Wang L. Abraxane® versus Taxol® for patients with advanced breast cancer: a prospective time and motion analysis from a Chinese health care perspective. J Oncol Pharm Pract. 2016;22(2):205–211. doi:10.1177/1078155214556008
   PubMed Web of Science ®Google Scholar
• RxList [homepage on the Internet]. DOXIL; 2022. Available from: https://www.rxlist.com/doxil-drug.htm. Accessed September 23, 2023.
   Google Scholar
• Metharom E, Galettis P, Manners S, et al. The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C. Asia Pac J Clin Oncol. 2011;7(1):65–74. doi:10.1111/j.1743-7563.2010.01354.x
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121(6):898–904. doi:10.1182/blood-2012-08-452839
   PubMed Web of Science ®Google Scholar